We are monitoring the impact of COVID-19 & Recession alarm on North America Schizophrenia Drugs Market Get in touch with us for detailed analysis Know More

Know More

Share on

North America Schizophrenia Drugs Market Research Report – Segmented By Therapeutic Class, Treatment & Country (the United States, Canada and Rest of North America) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 8017
Pages: 145

The size of the North America Schizophrenia Drugs Market was worth USD 2.35 billion in 2022 and estimated to be growing at a CAGR of 2.24%, to reach USD 2.63 billion by 2027. 

The market in this region is likely to be driven by a growth in the number of patients receiving treatment and a rising desire for better healthcare infrastructure. In recent years, governments have worked closely with several hospitals to safeguard individuals against schizophrenia. In addition, pharmaceutical companies are investing more in schizophrenia drug research and development to create treatments that go beyond the dopaminergic hypothesis of schizophrenia and monoamine G protein-coupled receptors (GPCRs). They're ramping up the production of dopamine antagonists and other medications designed to treat schizophrenia symptoms and successfully improve patient quality of life.

To minimize amphetamine-induced behavioral abnormalities in patients, manufacturers of schizophrenia medications turn to alternative second-generation antipsychotics like serotonin and histamine. The market is growing because of the rising prevalence of the condition and the increasing need to manage it effectively. The schizophrenia drug market will also be fueled by increased awareness of mental diseases, rising healthcare spending, and the availability of effective treatment approaches, as well as a desire for target-specific and personalized treatments.

However, the rising expense of mental health services and the prevalence of substance misuse are likely to stifle market expansion. In addition, the rise in cases of addiction linked to these drugs and the expiration of essential drug patents are stifling total market growth. The United States is the world's most COVID-affected country. This country's product supply chain was severely damaged. Initially, there has been a drop in demand for schizophrenia medications, which has harmed total market growth.

This research report on the North American schizophrenia drugs market has been segmented and sub-segmented into the following categories.

By Therapeutic Class:

  • Second generation anti-psychotics
    • Risperdal
    • Invega
    • Zyprexa
    • Geodon
    • Seroquel
    • Latuda
    • Aristada
    • Fanapt
    • Saphris
    • Vraylar
  • Third generation anti-psychotics  
  • Others    

By Treatment:

  • Oral anti-psychotics       
  • Injectable anti-psychotics 

By Country:

  • The United States
  • Canada
  • Rest of North America

Over the forecast period, the North American region is expected to lead the global market. The United States accounted for the most significant market share in the North American area, as a large portion of the population turns to such pharmacological therapy due to their hectic lifestyles. Furthermore, the country provides modern medical care with early treatment capabilities and government involvement in raising healthcare spending. The American Psychiatric Association's mission is to diminish this psychiatric disorder's mortality, morbidity, and substantial psychological and health implications. As a result, such government measures boost North America's total market growth.

In addition, technological improvements in the production of new pharmaceuticals, rising healthcare expenditures, and well-established healthcare infrastructure contribute to the overall regional market's growth. Because of the increased frequency of schizophrenia, the growing geriatric population, and rising demand for schizophrenia treatment, the Americas are predicted to have dominated the global schizophrenia market. Schizophrenia, according to the Treatment Advocacy Center, is a chronic and severe neurological brain condition that impacted roughly 2.6 million persons in the United States aged 18 and older in 2015. Furthermore, increased awareness campaigns are propelling the market forward. For example, mental Health America (MHA) has launched the B4Stage4 campaign, which aims to raise awareness of the mental illness and encourage early detection and intervention.

KEY MARKET PLAYERS:

Some of the major companies dominating the market by their products and services include Johnson & Johnson, Sumitomo Dainippon, Eli Lilly, Bristol-Myers Squibb/ Otsuka Pharma, AstraZeneca, Alkermes, Vanda Pharma, Allergan, and Pfizer.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Therapeutic class                     

                                5.1.1 Introduction           

                                5.1.2 Second generation anti-psychotics               

                                                5.1.2.1 Risperdal

                                                5.1.2.2 Invega

                                                5.1.2.3 Zyprexa

                                                5.1.2.4 Geodon

                                                5.1.2.5 Seroquel

                                                5.1.2.6 Latuda

                                                5.1.2.7 Aristada

                                                5.1.2.8 Fanapt

                                                5.1.2.9 Saphris

                                                5.1.2.10 Vraylar

                                5.1.3 Third generation anti-psychotics   

                                5.1.4 Others      

                                5.1.5  Y-o-Y Growth Analysis, By Therapeutic class            

                                5.1.6  Market Attractiveness Analysis, By Therapeutic class          

                                5.1.7  Market Share Analysis, By Therapeutic class           

                5.2 Treatment                  

                                5.2.1 Introduction           

                                5.2.2 Oral anti-psychotics             

                                5.2.3 Injectable anti-psychotics 

                                5.2.4 Y-o-Y Growth Analysis, By Treatment          

                                5.2.5 Market Attractiveness Analysis, By Treatment        

                                5.2.6 Market Share Analysis, By Treatment         

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Therapeutic class

                                                6.1.3.3 By Treatment

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Therapeutic class

                                                6.1.4.3 By Treatment

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 Therapeutic class

                                                6.1.5.3 By Treatment

                6.2 United States                            

                6.3 Canada                         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Johnson & Johnson                 

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 AstraZeneca                               

                8.4 Sumitomo Dainippon                             

                8.5 Eli Lilly                           

                8.6 Alkermes                     

                8.7 Vanda Pharma                          

                8.8 Allergan                       

                8.9 Pfizer                            

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  2. North America Second generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  3. North America Third generation anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  4. North America Others Market, By Region, From 2022 - 2027 (USD Billion)
  5. North America Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
  6. North America Oral anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  7. North America Injectable anti-psychotics Market, By Region, From 2022 - 2027 (USD Billion)
  8. United States Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  9. United States Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)
  10. Canada Schizophrenia Drugs Market, By Therapeutic class, From 2022 - 2027 (USD Billion)
  11. Canada Schizophrenia Drugs Market, By Treatment, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample